SURPASS-2
Tirzepatide versus Semaglutide in Type 2 Diabetes
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 1,879 patients with T2DM on metformin, tirzepatide 5, 10 or 15 mg weekly reduced HbA1c and body weight more than semaglutide 1 mg weekly.
N
1 879
Schéma
Open-label RCT, 40 weeks
Critère
Change in HbA1c at week 40
Pertinence
3
RésultatHbA1c −2.01/−2.24/−2.30 % vs −1.86 %; weight loss up to −11.2 kg vs −5.7 kg. All three doses superior to semaglutide (p<0.001).
Frías JP, et al. N Engl J Med. 2021;385(6):503-515. 10.1056/NEJMoa2107519
Discussion et critique
Established tirzepatide as the most potent glucose- and weight-lowering injectable for T2DM. SURPASS-CVOT (2025) later confirmed non-inferior CV outcomes vs dulaglutide.